University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research - New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

The Global Pathogen Analysis System is being provided as a free resource to help combat COVID-19 and other microbial health threats. Join the program and learn more at: www.gpas.cloud

Built using Oxford’s Scalable Pathogen Pipeline Platform (SP3), Oracle APEX, and Oracle Cloud Infrastructure(OCI), the Global Pathogen Analysis System is a cloud platform that provides a unified, standardized system for analyzing and comparing the annotated genomic sequence data of SARS-CoV-2. Researchers are using the system to upload pathogen data and receive comprehensive results within minutes. With user permission, the results may be shared with participating laboratories around the globe in a secure environment. Making this data comprehensible and shareable will help public health authorities evaluate and plan their response by giving them invaluable insight into emerging variants even before they are officially designated as Variants of Concern.

Uniting the global research community in a common mission

"GPAS is the first industry standards-based service anywhere in the world, offering a standardised sequence data analysis service for users on the cloud," said Derrick Crook, professor of microbiology in the University of Oxford's Nuffield Department of Medicine. "Users will be able to access, upload and process their sequence data fully under their sovereign control and receive back fully analysed data in as little as 20 minutes of successful upload. If they select to share data, they will contribute to electronic dashboard visualisations of global data revealing the daily changes in the way the pandemic is progressing and how the virus is changing. This will enable continuous assessment of the pandemic and help guide national and global interventions to curb the impact of the virus."

"COVID-19 is a global fight, yet researchers have lacked the technical infrastructure to process raw sequences quickly, securely and share those results worldwide," said Oracle Chairman and CTO, Larry Ellison. "With GPAS, we are bringing the power and security of the cloud to enable any researcher, in any location to become part of the solution. The more data that medical institutions, governments, and academics provide, the more quickly we can understand and act to get ahead of the coronavirus."

Using the platform, researchers and governments will be able to quickly access the timely, relevant data they need to make up-to-date scientific analysis and better informed policy and safety decisions regarding new variants. As part of their work with the Global Health Security Consortium (GHSC), the Lawrence J. Ellison Institute for Transformative Medicine (Ellison Institute) and the Tony Blair Institute (TBI) for Global Change have worked in coordination with Oxford and Oracle to support the development of the platform and to get it in the hands of global researchers.

"The world's lack of preparedness for the COVID-19 pandemic has highlighted our need to work differently in order to identify solutions that are pragmatic and able to scale in the face of challenges," said Dr. David B. Agus, GHSC Member and CEO, Ellison Institute. "GPAS is a key building block in the global data infrastructure for early warning systems and global surveillance."

"We know only too well that viruses do not respect borders which is why we must take a global, single-minded approach to contain this pandemic," said Tony Blair, Executive Chairman of TBI and former UK Prime Minister. "This platform promises to bring together data much more rapidly, helping us to better understand and get ahead of the patterns of spread faster, so governments can make better policy decisions and mitigate the devastating impact this virus continues to inflict in their own countries and across the globe."

To get involved in this initiative, please visit: www.gpas.cloud

About the University of Oxford

The University of Oxford has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation.

Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.

Through its research commercialization arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.

About the Global Health Security Consortium

The Global Health Security Consortium (GHSC) provides insight, analysis and support for leaders around the world to help them deal with COVID-19 today and prepare for the health security challenges of tomorrow. It is a joint initiative of the Tony Blair Institute for Global Change, the Ellison Institute for Transformative Medicine, and a team of scientists at the University of Oxford.

Most Popular Now

COVID-19 vaccine protection wanes after three mont…

The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets...

New study adds more evidence for Omicron immune ev…

A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune p...

European Commission grants conditional marketing a…

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announce...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Vaxzevria significantly boosted antibody levels ag…

AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose boo...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...